The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 756 participants.
Also called NCT01137812
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 756 participants
- Registry
-
NCT01137812
-
- Other papers using this trial's data
- Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, India, Israel, Malaysia, Netherlands, New Zealand, Poland, Singapore, South Korea, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01137812. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Canagliflozin 300 mg
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulphonylurea
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01137812- Content hash
4f628cd5c8c5694e1528636a1efe8680d50288029634aa8425d606640c69e945